Life with continuous subcutaneous insulin infusion (CSII) therapy: child and parental perspectives and predictors of metabolic control
- PMID: 15016198
- DOI: 10.1034/j.1399-5448.2001.002002051.x
Life with continuous subcutaneous insulin infusion (CSII) therapy: child and parental perspectives and predictors of metabolic control
Abstract
Objective: The purpose of this study was twofold (i): to evaluate metabolic control in patients receiving CSII therapy in a routine pediatric diabetes clinic by describing reasons for initiating therapy and daily management issues, including needle fear; and (ii) to assess the change in parental involvement and anxiety once their child initiated CSII therapy.
Research design and methods: The study included 52 subjects (aged 7.6-23.6 yr) from a general pediatric diabetes clinic. Management issues were defined as diet, exercise, home blood glucose monitoring (HBGM) frequency, and self/staff assessment of needle fear. Characteristics were analyzed both according to a 0.5% change in HbA1c status (decreased vs. stable vs. increased) compared with pre-CSII therapy, and final HbA1c achieved (< or = 8.1 vs. > 8.1%).
Results: The primary recommendation source for CSII use was most often the physician/diabetes team (48.1%), followed by a combination of the former with a personal referral source (32.7%). The most common reason (71.2%) for CSII initiation was a combination of wanting to achieve better metabolic control, dislike of insulin injections, and/or increased flexibility in daily living. Over one-quarter (26.9%) of subjects were identified as being needle-fearful, and this characteristic was predictive of final metabolic control (3/25 subjects </= 8.1% vs. 11/27 subjects > 8.1%, p = 0.03). On CSII therapy, dietary carbohydrate consistency was highly variable, and most subjects (65.3%) exclusively used an insulin to carbohydrate ratio for insulin bolus dosage calculation. The most common adjustment strategy (63.5%) for exercise was a combination of decreasing the insulin basal rate, disconnecting the pump, and/or eating extra carbohydrates. For the total cohort, the frequency of HBGM significantly increased on CSII therapy (4.31-4.85 tests/day, p = 0.02). Females did not have a significant change in HBGM frequency, while the youngest subjects had the highest HBGM frequency. Parental involvement and anxiety primarily stayed the same or decreased, regardless of the child's age (< or = 18 vs. > 18 yr) or metabolic control.
Conclusions: Analyses of the various characteristics identified only needle fearfulness as being predictive of poor metabolic control. Interestingly, poor control with CSII therapy did not result in a significant increase in parental involvement and/or anxiety.
Comment in
-
Continuous subcutaneous insulin infusion and continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: boon or bane?Pediatr Diabetes. 2001 Jun;2(2):49-50. doi: 10.1046/j.1399-543x.2001.00001.x. Pediatr Diabetes. 2001. PMID: 15016197 No abstract available.
Similar articles
-
Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria.Exp Clin Endocrinol Diabetes. 2006 Jul;114(7):384-8. doi: 10.1055/s-2006-924152. Exp Clin Endocrinol Diabetes. 2006. PMID: 16915542
-
[Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus].Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2005;11(3):171-6. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2005. PMID: 16232370 Clinical Trial. Polish.
-
Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups.Pediatr Diabetes. 2002 Mar;3(1):10-5. doi: 10.1034/j.1399-5448.2002.30103.x. Pediatr Diabetes. 2002. PMID: 15016169
-
Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.Exp Clin Endocrinol Diabetes. 2009 Sep;117(8):378-85. doi: 10.1055/s-0029-1225337. Epub 2009 Jul 23. Exp Clin Endocrinol Diabetes. 2009. PMID: 19629931
-
[Continuous subcutaneous insulin infusion (CSII) in treating young diabetic patients].Przegl Lek. 2005;62(1):49-53. Przegl Lek. 2005. PMID: 16053222 Review. Polish.
Cited by
-
Insulin pump therapy: impact on the lives of children/young people with diabetes mellitus and their parents.Int J Clin Pharm. 2014 Oct;36(5):1023-30. doi: 10.1007/s11096-014-9990-1. Epub 2014 Aug 10. Int J Clin Pharm. 2014. PMID: 25108411
-
Parental involvement buffers associations between pump duration and metabolic control among adolescents with type 1 diabetes.J Pediatr Psychol. 2010 Nov;35(10):1152-60. doi: 10.1093/jpepsy/jsq012. Epub 2010 Mar 10. J Pediatr Psychol. 2010. PMID: 20219778 Free PMC article.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical